Dearden N M
Neuroanasthesia, Leeds University, UK.
Clin Neuropathol. 1998 Jul-Aug;17(4):221-8.
The injured brain may be damaged by primary impact, secondary injury from secondary damage due to initiation of destructive inflammatory and biochemical cascades by the primary injury or secondary ischemic injury following secondary insults that initiate or augment these immunological and biochemical cascades. Cerebral ischemia will arise whenever delivery of oxygen and substrates to the brain fall below metabolic needs. Many factors lead to the development of secondary insults to the injured brain during initial resuscitation, transport, surgery, and subsequent intensive care. Continuous monitoring of cerebral oxygenation (jugular oximetry, brain tissue PO2) and cerebral blood flow velocity (transcranial Doppler ultrasonography) in patients with brain trauma reveals multiple episodes of transient hypoperfusion with an adverse relationship between incidence and outcome. Secondary brain insults arise through systemic or intracranial mechanisms that reduce cerebral blood flow from compromised CPP, vascular distortion or cerebrovascular narrowing or lower oxygen delivery from hypoxemia associated with airway obstruction, pulmonary pathology, or anemia. Secondary brain ischemia remains a common pathway to secondary brain damage in most critically ill neurosurgical patients. In the future prevention of secondary brain injury may well hinge on giving a cocktail of novel agents that modify destructive biochemical and inflammatory pathways, each having a potential therapeutic window possibly in a subgroup of patients. To date, phase 3 clinical trials of several agents including PEGSOD and tyrilizad mesylate have failed to show relevant efficacy after brain trauma or subarachnoid hemorrhage. The therapeutic role of calcium channel blockers in traumatic subarachnoid hemorrhage is currently under investigation following the results of subgroup metaanalysis. Several phase 3, NMDA receptor antagonist studies are underway in brain trauma with results expected soon. Although we know that secondary insults promote excitotoxic secondary brain damage there is currently no pharmacological intervention with proven efficacy and, therefore, detection and correction of secondary insults appear to offer the best therapeutic strategy. After brain trauma, systemic hypotension, compromised CPP, raised ICP, elevated temperature, hypoxemia, and jugular bulb venous desaturation are associated with poor prognosis. Clinical trials of moderate hypothermia following brain trauma are ongoing. Following adult brain trauma maintenance of CPP above at least 65 mmHg (probably > 40 mmHg in children below 8 years) seems important to improve outcome indicating the need for continuous ICP monitoring during intensive care of brain-injured patients.
受伤的大脑可能会受到原发性撞击的损伤,也可能因原发性损伤引发的破坏性炎症和生化级联反应导致继发性损伤,或者在引发或加剧这些免疫和生化级联反应的继发性损伤后出现继发性缺血性损伤。只要大脑的氧气和底物供应低于代谢需求,就会发生脑缺血。在初始复苏、转运、手术及后续重症监护期间,许多因素会导致受伤大脑受到继发性损伤。对脑外伤患者持续监测脑氧合(颈静脉血氧饱和度、脑组织氧分压)和脑血流速度(经颅多普勒超声检查)发现,存在多次短暂性灌注不足,其发生率与预后呈负相关。继发性脑损伤通过全身或颅内机制发生,这些机制会因脑灌注压受损、血管扭曲或脑血管狭窄而减少脑血流量,或者因气道阻塞、肺部病变或贫血导致的低氧血症而降低氧输送。在大多数重症神经外科患者中,继发性脑缺血仍然是继发性脑损伤的常见途径。未来,预防继发性脑损伤可能很大程度上依赖于给予一组新型药物,这些药物可改变破坏性生化和炎症途径,每种药物可能在部分患者亚组中具有潜在的治疗窗。迄今为止,包括聚乙二醇超氧化物歧化酶和甲磺酸替拉扎特在内的几种药物的3期临床试验在脑外伤或蛛网膜下腔出血后均未显示出相关疗效。根据亚组荟萃分析结果,目前正在研究钙通道阻滞剂在创伤性蛛网膜下腔出血中的治疗作用。几项3期N-甲基-D-天冬氨酸受体拮抗剂研究正在脑外伤患者中进行,预计很快会有结果。虽然我们知道继发性损伤会促进兴奋性毒性继发性脑损伤,但目前尚无经证实有效的药物干预措施,因此,检测和纠正继发性损伤似乎是最佳治疗策略。脑外伤后,系统性低血压、脑灌注压受损、颅内压升高、体温升高、低氧血症和颈静脉球静脉血氧饱和度降低与预后不良相关。脑外伤后中度低温的临床试验正在进行。对于成人大脑外伤,将脑灌注压维持在至少65 mmHg以上(8岁以下儿童可能>40 mmHg)似乎对改善预后很重要,这表明在脑损伤患者的重症监护期间需要持续监测颅内压。